Department of Gynecology and Obstetrics, Medical University Innsbruck, Anichstrasse 35, Innsbruck, Austria.
Int J Gynecol Pathol. 2011 Nov;30(6):527-31. doi: 10.1097/PGP.0b013e31821ac519.
The p73 gene gives rise to the full-length transactivation competent TAp73 and the N-terminally truncated isoform ΔNp73, which inhibits TAp73 and wild-type p53. The clinical relevance of TAp73 and ΔNp73 protein expression has not yet been evaluated in ovarian cancer. TAp73 and ΔNp73 expression was examined using immunohistochemistry and reverse transcription-polymerase chain reaction in 83 and 64 ovarian cancer specimens, respectively. A yeast-based assay and subsequent sequencing were performed to analyze the p53 mutational status. TAp73 and ΔNp73 protein expression was found in 73 of 83 (88%) and 48 of 83 (57.8%) ovarian cancer samples, respectively. The majority of cases showed immunostaining in both the nucleus and cytoplasm of tumor cells. TAp73 and ΔNp73 protein expression correlated with messenger RNA quantification in 25 of 64 (39.1%) and 37 of 64 (57.8%) cancer specimens, respectively. TAp73 and ΔNp73 protein expression was not associated with the p53 mutational status, clinicopathologic parameters, and prognosis of the examined ovarian cancer cases. Although TAp73 and ΔNp73 protein expression did not possess prognostic significance for ovarian cancer in this study, a potential clinical role of p73 isoforms cannot be definitively excluded due to limitations of immunohistochemistry.
p73 基因产生全长转录激活 competent TAp73 和 N 端截断的异构体 ΔNp73，后者抑制 TAp73 和野生型 p53。TAp73 和 ΔNp73 蛋白表达在卵巢癌中的临床相关性尚未得到评估。使用免疫组织化学和逆转录-聚合酶链反应分别在 83 例和 64 例卵巢癌标本中检测 TAp73 和 ΔNp73 的表达。进行了酵母测定和随后的测序，以分析 p53 突变状态。在 83 例卵巢癌样本中，73 例（88%）存在 TAp73 蛋白表达，48 例（57.8%）存在 ΔNp73 蛋白表达。大多数病例在肿瘤细胞的核和细胞质中均显示免疫染色。在 25 例（39.1%）和 37 例（57.8%）癌症标本中，TAp73 和 ΔNp73 蛋白表达与信使 RNA 定量相关。TAp73 和 ΔNp73 蛋白表达与 p53 突变状态、临床病理参数和所检查的卵巢癌病例的预后无关。尽管在本研究中，TAp73 和 ΔNp73 蛋白表达对卵巢癌没有预后意义，但由于免疫组织化学的局限性，不能明确排除 p73 异构体的潜在临床作用。
